Cited by 571Bacterial Infections and VaccinesMicrobial infections and disease researchNeonatal and Maternal Infections

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

Trotter, Caroline L, Andrews, Nick J, Kaczmarski, Edward B, Miller, Elizabeth, Ramsay, Mary E·2004·The Lancet

Open this paper in CoChat — free account

Abstract

The meningococcal serogroup C conjugate (MCC) vaccine programme in England has successfully controlled the incidence of serogroup C disease, as a result of high short-term vaccine effectiveness and substantial herd immunity. However, the long-term effectiveness of the vaccine remains unknown. We assessed surveillance data from the 4 years since introduction of the programme. Vaccine effectiveness remained high in children vaccinated in the catch-up campaign (aged 5 months to 18 years). However, for children vaccinated in the routine infant immunisation programme, the effectiveness of the MCC vaccine fell to low levels after only 1 year. The number of individuals in these cohorts remains low, but alternative routine immunisation schedules should be considered to ensure high levels of protection are sustained.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(04)16725-1

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story
Miller, E. J., SALISBURY, D. M., & Ramsay, M. E. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00299-7 · Cited by 483
Self-citation
Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis
Ramsay, M. E., Andrews, N. J., Trotter, C. L., Kaczmarski, E. B., & Miller, E. (2003) · BMJ · doi:10.1136/bmj.326.7385.365 · Cited by 409
Self-citation
Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England
Ramsay, M. E., Andrews, N. J., Kaczmarski, E. B., & Miller, E. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03594-7 · Cited by 337
Self-citation
Estimating Haemophilus influenzae Type b Vaccine Effectiveness in England and Wales by Use of the Screening Method
Ramsay, M. E., McVernon, J., Andrews, N. J., Heath, P. T., & Slack, M. P. (2003) · The Journal of Infectious Diseases · doi:10.1086/376997 · Cited by 172
Self-citation
Antibody Persistence and Immunological Memory at Age 4 Years after Meningococcal Group C Conjugate Vaccination in Children in the United Kingdom
Borrow, R., Goldblatt, D., Andrews, N. J., Southern, J., Ashton, L., Deane, S., Morris, R., Cartwright, K. A. V., & Miller, E. (2002) · The Journal of Infectious Diseases · doi:10.1086/344324 · Cited by 114
Self-citation

Show all 5 references

Research works printed but not linked: 1

Quarterly Communicable Disease Reports on the COVER programme for childhood immunisation

Sorted by citations

A guide to vaccinology: from basic principles to new developments
Pollard, A. J., & Bijker, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00479-7 · Cited by 1,593
Epidemic meningitis, meningococcaemia, and Neisseria meningitidis
Stephens, D. S., Greenwood, B., & Brandtzaeg, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61016-2 · Cited by 978
B-cell responses to vaccination at the extremes of age
Siegrist, C.-A., & Aspinall, R. (2009) · Nature Reviews Immunology · doi:10.1038/nri2508 · Cited by 659
Immunisation against infectious disease
SALISBURY, D. M., Ramsay, M. E., & Noakes, K. (2006) · Stationery Office eBooks · Cited by 636
Self-citation
Bacterial meningitis in children
Sáez‐Llorens, X., & McCracken, G. H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13693-8 · Cited by 543
Maintaining protection against invasive bacteria with protein–polysaccharide conjugate vaccines
Pollard, A. J., Perrett, K. P., & Beverley, P. C. L. (2009) · Nature reviews. Immunology · doi:10.1038/nri2494 · Cited by 485
Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity
Maiden, M. C. J., Ibarz-Pavón, A. B., Urwin, R., Gray, S. J., Andrews, N. J., Clarke, S. C., Walker, A. M., Evans, M. R., Kroll, J. S., Neal, K. R., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/527401 · Cited by 442
Self-citation
Neisseria meningitidis: Biology, Microbiology, and Epidemiology
Rouphael, N., & Stephens, D. S. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-346-2_1 · Cited by 435
Meningococcal surrogates of protection?serum bactericidal antibody activity
Borrow, R., Balmer, P., & Miller, E. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.051 · Cited by 414
Self-citation
APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells
Belnoue, E., Pihlgren, M., McGaha, T. L., Tougne, C., Rochat, A., Bossen, C., Schneider, P., Huard, B., Lambert, P., & Siegrist, C. (2008) · Blood · doi:10.1182/blood-2007-09-110858 · Cited by 365
Design considerations for liposomal vaccines: Influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens
Watson, D. S., Endsley, A. N., & Huang, L. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.070 · Cited by 339
Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial
Read, R. C., Baxter, D. N., Chadwick, D., Faust, S. N., Finn, A. H. R., Gordon, S. B., Heath, P. T., Lewis, D. J., Pollard, A. J., Turner, D. P. J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60842-4 · Cited by 282
Protein carriers of conjugate vaccines: Characteristics, development and clinical trials
Pichichero, M. E. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.26109 · Cited by 263
Advances in the Development of Vaccines againstNeisseria meningitidis
Tan, L., Carlone, G. M., & Borrow, R. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0906357 · Cited by 233
Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit
Gray, S. J. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46288-0 · Cited by 221
Immunogenicity of a Tetravalent Meningococcal Glycoconjugate Vaccine in Infants
Snape, M. D., Perrett, K. P., Ford, K. J., John, T. M., Pace, D., Yu, L., Langley, J. M., McNeil, S., Dull, P. M., Ceddia, F., et al. (2008) · JAMA · doi:10.1001/jama.2007.29-c · Cited by 215
Vaccine immunology
Siegrist, C. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-3611-1.50006-4 · Cited by 216
Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd Immunity
Campbell, H. J., Andrews, N. J., Borrow, R., Trotter, C. L., & Miller, E. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00529-09 · Cited by 213
Self-citation
Bacterial Meningitis in Children
Chávez‐Bueno, S., & McCracken, G. H. (2005) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2005.02.011 · Cited by 205
Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs
Trotter, C. L., & Maiden, M. C. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.48 · Cited by 203
Self-citation
Conquering the Meningococcus
Stephens, D. S. (2007) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2006.00051.x · Cited by 203
Neisseria meningitidis group B correlates of protection and assay standardization—International Meeting Report Emory University, Atlanta, Georgia, United States, 16–17 March 2005
Borrow, R., Carlone, G. M., Rosenstein, N. E., Blake, M., Feavers, I. M., Martin, D., Zollinger, W. D., Robbins, J., Aaberge, I. S., Granoff, D. M., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.03.091 · Cited by 197
Self-citation
Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup BNeisseria meningitidis
Murphy, E., Andrew, L., Lee, K., Dilts, D. A., Nuñez, L., Fink, P. S., Ambrose, K. D., Borrow, R., Findlow, J., Taha, M., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/600141 · Cited by 196
Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease
Frasch, C. E., Borrow, R., & Donnelly, J. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.065 · Cited by 190
Review of Meningococcal Group B Vaccines
Granoff, D. M. (2010) · Clinical Infectious Diseases · doi:10.1086/648966 · Cited by 189
Clinicians’ gut feeling about serious infections in children: observational study.
Van den Bruel, A., Thompson, M., Buntinx, F., & Mant, D. (2012) · BMJ · doi:10.1136/bmj.e6144 · Cited by 183
Can successful vaccines teach us how to induce efficient protective immune responses?
Lambert, P., Liu, M., & Siegrist, C. (2005) · Nature Medicine · doi:10.1038/nm1216 · Cited by 187
The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004–2014
Whittaker, R., Dias, J. G., Ramliden, M., Ködmön, C., Economopoulou, A., Beer, N., Pastore Celentano, L., Kanitz, E., Richter, L., Mattheus, W., et al. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.03.007 · Cited by 179
Prospects for Vaccine Prevention of Meningococcal Infection
Harrison, L. H. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.1.142-164.2006 · Cited by 178
Dynamic Models of Meningococcal Carriage, Disease, and the Impact of Serogroup C Conjugate Vaccination
Trotter, C. L., Gay, N. J., & Edmunds, W. J. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi160 · Cited by 176
Self-citation
Seroepidemiology: an underused tool for designing and monitoring vaccination programmes in low‐ and middle‐income countries
Cutts, F. T., & Hanson, M. (2016) · Tropical Medicine & International Health · doi:10.1111/tmi.12737 · Cited by 176
Meningococcal carriage in the African meningitis belt
Trotter, C. L., & Greenwood, B. M. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70288-8 · Cited by 174
Self-citation
Meningococcal polysaccharide–protein conjugate vaccines
Snape, M. D., & Pollard, A. J. (2004) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(04)01251-4 · Cited by 174
Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain
Larrauri, A., Cano, R., García, M. J. S., & de Mateo, S. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.03.045 · Cited by 171
Meningococcal C conjugate vaccine: the experience in England and Wales
Campbell, H., Borrow, R., Salisbury, D., & Miller, E. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.067 · Cited by 168
Self-citation
Outer membrane vesicles from group B Neisseria meningitidis Δgna33 mutant: Proteomic and immunological comparison with detergent‐derived outer membrane vesicles
Ferrari, G., Garaguso, I., Adu‐Bobie, J., Doro, F., Taddei, A. R., Biolchi, A., Brunelli, B., Giuliani, M. M., Pizza, M., Norais, N., et al. (2006) · PROTEOMICS · doi:10.1002/pmic.200500164 · Cited by 168
Mortality and morbidity in community-acquired sepsis in European pediatric intensive care units: a prospective cohort study from the European Childhood Life-threatening Infectious Disease Study (EUCLIDS)
Boeddha, N. P., Schlapbach, L. J., Driessen, G. J. A., Herberg, J. A., Calle, I. R., Cebey‐López, M., Klobassa, D. S., Philipsen, R. L. A., de Groot, R., Inwald, D. P., et al. (2018) · Critical Care · doi:10.1186/s13054-018-2052-7 · Cited by 162
Global Epidemiology of Meningococcal Disease and Vaccine Efficacy
Pollard, A. J. (2004) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000147642.85129.05 · Cited by 161
Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines
Trotter, C. L., & Ramsay, M. E. (2006) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2006.00053.x · Cited by 159
Self-citation
The Meningitis Vaccine Project
LaForce, F. M., Konde, K., Viviani, S., & Préziosi, M. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.04.049 · Cited by 158
Safety, Immunogenicity, and Immune Memory of a Novel Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (MCV-4) in Healthy Adolescents
KEYSERLING, H. L., Papa, T., Koranyi, K., Ryall, R., Bassily, E. L., Bybel, M. J., Sullivan, K., Gilmet, G., & Reinhardt, A. (2005) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.159.10.907 · Cited by 156
Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: A persistent problem with an imminent solution
LaForce, F. M., Ravenscroft, N., Djingarey, M. H., & Viviani, S. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.062 · Cited by 150
A surveillance network for meningococcal disease in Europe
Trotter, C. L., Chandra, M., Cano, R., Larrauri, A., Ramsay, M. E., Brehony, C., Jolley, K. A., Maiden, M. C. J., Heuberger, S., & Frosch, M. (2006) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2006.00060.x · Cited by 149
Self-citation
10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix™
Prymula, R., & Schuerman, L. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.113 · Cited by 146
Clinical and Immunologic Risk Factors for Meningococcal C Conjugate Vaccine Failure in the United Kingdom
Auckland, C., Gray, S., Borrow, R., Andrews, N. J., Goldblatt, D., Ramsay, M. E., & Miller, E. (2006) · The Journal of Infectious Diseases · doi:10.1086/509619 · Cited by 143
Self-citation
Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study
Christensen, H., Trotter, C. L., Hickman, M., & Edmunds, W. J. (2014) · BMJ · doi:10.1136/bmj.g5725 · Cited by 142
Self-citation
Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae
Trotter, C. L., McVernon, J., Ramsay, M. E., Whitney, C. G., Mulholland, K., Goldblatt, D., Hombach, J., & Kiény, M.-P. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.05.073 · Cited by 140
Self-citation
Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact
Christensen, H., Hickman, M., Edmunds, W. J., & Trotter, C. L. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.03.034 · Cited by 130
Self-citation
Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections
Sprong, T. (2006) · Blood · doi:10.1182/blood-2005-07-2820 · Cited by 133
Epidemiological Profile of Meningococcal Disease in the United States
Harrison, L. H. (2010) · Clinical Infectious Diseases · doi:10.1086/648963 · Cited by 134
PROTECTION FROM ROUTINE VACCINATION AT THE AGE OF 14 MONTHS WITH MENINGOCOCCAL SEROGROUP C CONJUGATE VACCINE IN THE NETHERLANDS
de Greeff, S. C., de Melker, H. E., Spanjaard, L., Schouls, L. M., & ENDE, A. V. D. (2006) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000195594.41449.c6 · Cited by 130
Cost-Effectiveness of Conjugate Meningococcal Vaccination Strategies in the United States
Shepard, C. W., Ortega‐Sanchez, I. R., Scott, R. D., Rosenstein, N. E., & and the ABCs Team (2005) · PEDIATRICS · doi:10.1542/peds.2004-2514 · Cited by 124
Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study
Snape, M. D., Kelly, D. F., Lewis, S. C., Banner, C., Kibwana, L., Moore, C. E., Diggle, L., John, T. M., Yu, L., Borrow, R., et al. (2008) · BMJ · doi:10.1136/bmj.39563.545255.ae · Cited by 123
Kinetics of Antibody Persistence following Administration of a Combination Meningococcal Serogroup C and Haemophilus influenzae Type b Conjugate Vaccine in Healthy Infants in the United Kingdom Primed with a Monovalent Meningococcal Serogroup C Vaccine
Borrow, R., Andrews, N. J., Findlow, H., Waight, P., Southern, J., Crowley-Luke, A., Stapley, L., England, A., Findlow, J., & Miller, E. (2009) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00384-09 · Cited by 115
Self-citation
Multicenter Surveillance of Invasive Meningococcal Infections in Children
Kaplan, S. L., Schutze, G. E., Leake, J. A. D., Barson, W. J., Halasa, N., Byington, C. L., Woods, C. R., Tan, T. Q., Hoffman, J. A., Wald, E. R., et al. (2006) · PEDIATRICS · doi:10.1542/peds.2006-0281 · Cited by 113
The Magnitude of the Antibody and Memory B Cell Responses during Priming with a Protein-Polysaccharide Conjugate Vaccine in Human Infants Is Associated with the Persistence of Antibody and the Intensity of Booster Response
Rohner, G. B., Snape, M. D., Kelly, D. F., John, T. M., Morant, A., Yu, L., Borkowski, A., Ceddia, F., Borrow, R., Siegrist, C., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2165 · Cited by 114
Immunological Memory: The Role of B Cells in Long-term Protection Against Invasive Bacterial Pathogens
Kelly, D. F., Pollard, A. J., & Moxon, E. R. (2005) · JAMA · doi:10.1001/jama.294.23.3019 · Cited by 113
Polysaccharide structure dictates mechanism of adaptive immune response to glycoconjugate vaccines
Sun, X., Stefanetti, G., Berti, F., & Kasper, D. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816401115 · Cited by 112
Overview of the development and current use of CRM197 conjugate vaccines for pediatric use
Shinefield, H. R. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.04.072 · Cited by 112
British HIV Association guidelines for immunization of HIV‐infected adults 2008
Geretti, A. M. (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00637.x · Cited by 110
Immunisation handbook 2006
Blackmore, T., Buchan, G. S., Grant, C. C., Grimwood, K., LENNON, D. R., Murdoch, D. R., Pierce, J., Reid, S., & Roberts, A. (2006) · Cited by 108
From Pasteur to genomics: progress and challenges in infectious diseases
Rappuoli, R. (2004) · Nature Medicine · doi:10.1038/nm1129 · Cited by 112
Timeliness of childhood immunisation in Australia
Hull, B. P., & McIntyre, P. B. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.02.049 · Cited by 110
A Prospective Study of the Effectiveness of the New Zealand Meningococcal B Vaccine
Kelly, C., Arnold, R., Galloway, Y., & O'Hallahan, J. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm147 · Cited by 110
CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells
Kelly, D. F., Snape, M. D., Clutterbuck, E., Green, S., Snowden, C., Diggle, L., Yu, L., Borkowski, A., Moxon, E. R., & Pollard, A. J. (2006) · Blood · doi:10.1182/blood-2006-01-009282 · Cited by 107
Phase III Comparison of an Investigational Quadrivalent Meningococcal Conjugate Vaccine with the Licensed Meningococcal ACWY Conjugate Vaccine in Adolescents
Jackson, L. A., Baxter, R. P., Reisinger, K. S., Karsten, A., Shah, J., Bedell, L., Dull, P. M., & the V59P13 Study Group (2009) · Clinical Infectious Diseases · doi:10.1086/599117 · Cited by 107
Immunisation of premature infants
Bonhoeffer, J., Siegrist, C., & Heath, P. T. (2006) · Archives of Disease in Childhood · doi:10.1136/adc.2005.086306 · Cited by 106
Booster Vaccinations: Can Immunologic Memory Outpace Disease Pathogenesis?
Pichichero, M. E. (2009) · PEDIATRICS · doi:10.1542/peds.2008-3645 · Cited by 101
Effectiveness of a Mass Immunization Campaign Using Serogroup C Meningococcal Conjugate Vaccine
Wals, P. D. (2004) · JAMA · doi:10.1001/jama.292.20.2491 · Cited by 101
Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease
Melegaro, A., Choi, Y. H., George, R. C., Edmunds, W. J., Miller, E., & Gay, N. J. (2010) · BMC Infectious Diseases · doi:10.1186/1471-2334-10-90 · Cited by 99
Self-citation
Immune responses to polysaccharides: Lessons from humans and mice
González‐Fernández, Á., Faro, J., & Fernández, C. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.11.042 · Cited by 98
Lack of Serum Bactericidal Activity in Preschool Children Two Years After a Single Dose of Serogroup C Meningococcal Polysaccharide-Protein Conjugate Vaccine
Snape, M. D., Kelly, D. F., Green, B., Moxon, E. R., Borrow, R., & Pollard, A. J. (2005) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000151029.58752.27 · Cited by 98
Emergence of Endemic Serogroup W135 Meningococcal Disease Associated with a High Mortality Rate in South Africa
von Gottberg, A., du Plessis, M., Cohen, C., Prentice, E., Schrag, S. J., de Gouveia, L., Coulson, G., de Jong, G., Klugman, K. P., & Group for Enteric, R. A. M. D. S. I. S. A. (2008) · Clinical Infectious Diseases · doi:10.1086/525260 · Cited by 98
Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years
Østergaard, L. J., Lebacq, E., POOLMAN, J. T., Maechler, G., & Boutriau, D. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.08.075 · Cited by 97
Eliminating Epidemic Group A Meningococcal Meningitis In Africa Through A New Vaccine
LaForce, F. M., & Okwo‐Bele, J. (2011) · Health Affairs · doi:10.1377/hlthaff.2011.0328 · Cited by 97
Reduced Ability of Neonatal and Early-Life Bone Marrow Stromal Cells to Support Plasmablast Survival
Pihlgren, M., Friedli, M., Tougne, C., Rochat, A.-F., Lambert, P.-H., & Siegrist, C.-A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.165 · Cited by 94
Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention
Sáfadi, M. A. P., & Cintra, O. A. L. (2010) · Neurological Research · doi:10.1179/016164110x12644252260754 · Cited by 93
Neonatal and Infantile Immune Responses to Encapsulated Bacteria and Conjugate Vaccines
Klouwenberg, P. M. C. K., & Bont, L. (2008) · Clinical and Developmental Immunology · doi:10.1155/2008/628963 · Cited by 89
Reconsideration of the Use of Meningococcal Polysaccharide Vaccine
Granoff, D. M., & Pollard, A. J. (2007) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3180cc2c25 · Cited by 89
Effectiveness of meningococcal serogroup C vaccine programmes
Borrow, R., Abad, R., Trotter, C., van der Klis, F. R. M., & Vazquez, J. A. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.07.083 · Cited by 88
Self-citation
Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose
Snape, M. D., Saroey, P., John, T. M., Robinson, H., Kelly, S., Gossger, N., Yu, L., Wang, H., Toneatto, D., Dull, P. M., et al. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.130257 · Cited by 85
Antibody Persistence after Serogroup C Meningococcal Conjugate Immunization of United Kingdom Primary‐School Children in 1999–2000 and Response to a Booster: A Phase 4 Clinical Trial
Perrett, K. P., Winter, A. P., Kibwana, E., Jin, C., John, T. M., Yu, L., Borrow, R., Curtis, N. C., & Pollard, A. J. (2010) · Clinical Infectious Diseases · doi:10.1086/652765 · Cited by 83
Serogroup C Meningococcal Glycoconjugate Vaccine in Adolescents: Persistence of Bactericidal Antibodies and Kinetics of the Immune Response to a Booster Vaccine More Than 3 Years after Immunization
Snape, M. D., Kelly, D. F., Salt, P., Green, S., Snowden, C., Diggle, L., Borkowski, A., Yu, L., Moxon, E. R., & Pollard, A. J. (2006) · Clinical Infectious Diseases · doi:10.1086/508776 · Cited by 85
Vaccine immunology
Siegrist, C. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00004-5 · Cited by 93
Meningococcal vaccines
Granoff, D. M., Harrison, L. H., & Borrow, R. (2008) · Elsevier eBooks · doi:10.1016/b978-1-4160-3611-1.50023-4 · Cited by 84
A generic mechanism inNeisseria meningitidisfor enhanced resistance against bactericidal antibodies
Uría, M. J., Zhang, Q., Li, Y.-W., Chan, A., Exley, R. M., Gollan, B., Chan, H., Feavers, I. M., Yarwood, A., Abad, R., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072577 · Cited by 84
Effectiveness and Duration of Protection of One Dose of a Meningococcal Conjugate Vaccine
Cohn, A. C., MacNeil, J. R., Harrison, L. H., Lynfield, R., Reingold, A. L., Schaffner, W., Zell, E. R., Plikaytis, B. D., Wang, X., Messonnier, N. E., et al. (2017) · PEDIATRICS · doi:10.1542/peds.2016-2193 · Cited by 83
Regulation of capsule inNeisseria meningitidis
Tzeng, Y., Thomas, J. D., & Stephens, D. S. (2015) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2015.1022507 · Cited by 81
Two Decades of Experience With the Haemophilus influenzae Serotype b Conjugate Vaccine in the United Kingdom
Ladhani, S. N. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.11.027 · Cited by 79
Immunity against Neisseria meningitidis Serogroup C in the Dutch Population before and after Introduction of the Meningococcal C Conjugate Vaccine
de Voer, R. M., Mollema, L., Schepp, R. M., de Greeff, S. C., van Gageldonk, P. G. M., de Melker, H. E., Sanders, E. A. M., Berbers, G. A. M., & van der Klis, F. R. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012144 · Cited by 80
A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children
Knuf, M., Kieninger‐Baum, D., Habermehl, P., Muttonen, P., Maurer, H., Vink, P., POOLMAN, J. T., & Boutriau, D. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.10.064 · Cited by 79
Invasive Meningococcal Disease in the 21st Century—An Update for the Clinician
Dwilow, R., & Fanella, S. T. (2015) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-015-0524-6 · Cited by 79
Carrier priming or suppression: Understanding carrier priming enhancement of anti-polysaccharide antibody response to conjugate vaccines
Pobre, K., Tashani, M., Ridda, I., Rashid, H., Wong, M., & Booy, R. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.01.047 · Cited by 76
The Impact of Childhood Meningococcal Serogroup C Conjugate Vaccine Programs in Canada
Bettinger, J. A., Scheifele, D. W., Saux, N. L., Halperin, S. A., Vaudry, W., & Tsang, R. S. W. (2009) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31819040e7 · Cited by 76
Immunogenicity and Safety of a Combination Pneumococcal-Meningococcal Vaccine in Infants
Buttery, J. P., Riddell, A., McVernon, J., Chantler, T., Lane, L., Bowen‐Morris, J., Diggle, L., Morris, R., Harnden, A., Lockhart, S. P., et al. (2005) · JAMA · doi:10.1001/jama.293.14.1751 · Cited by 75
Antibody Persistence 3 Years after Immunization of Adolescents with Quadrivalent Meningococcal Conjugate Vaccine
Vu, D. M., Welsch, J. A., Zuno‐Mitchell, P., Cruz, J. V. D., & Granoff, D. M. (2006) · The Journal of Infectious Diseases · doi:10.1086/500512 · Cited by 74
Prevention and Control of Meningococcal Disease: Recommendations for Use of Meningococcal Vaccines in Pediatric Patients
(2005) · PEDIATRICS · doi:10.1542/peds.2005-1314 · Cited by 74
Vaccine Immunology
Siegrist, C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00002-x · Cited by 81
Glycoconjugate vaccines: an update
Vella, M., & Pace, D. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.993375 · Cited by 73
Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age
Kitchin, N. R. E., Southern, J., Morris, R., Hemme, F., Thomas, S., Watson, M. W., Cartwright, K. A. V., & Miller, E. (2006) · Archives of Disease in Childhood · doi:10.1136/adc.2005.076109 · Cited by 73
Self-citation

Authors: Trotter, C. L., Andrews, N. J., Kaczmarski, E. B., Miller, E., & Ramsay, M. E.
Affiliations: Manchester Royal Infirmary (GB)
ORCID: Trotter, Caroline L
Andrews, Nick J
Miller, Elizabeth
Ramsay, Mary E
Venue: The Lancet
Publisher: Elsevier BV
Published: 2004-07
Volume: 364
Issue: 9431
Pages: 365-367
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(04)16725-1
OpenAlex: W2160879811
Cited by: 571
References: 5
Citations by year: 2026: 1 · 2025: 4 · 2024: 1 · 2023: 6 · 2022: 7 · 2021: 10 · 2020: 12 · 2019: 15 · 2018: 18 · 2017: 26 · 2016: 23 · 2015: 33 · 2014: 27 · 2013: 29 · 2012: 42
FWCI: 50.77
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Explore Bristol Research (publishedVersion)
Topics: Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Life Sciences › Immunology and Microbiology › Microbiology › Microbial infections and disease research
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal and Maternal Infections
Keywords: vaccine effectiveness, long-term vaccine effectiveness, herd immunity, catch-up vaccination, meningococcal disease incidence, vaccination schedule, England
MeSH terms: Adolescent, Adult, Age Factors, Child, Child, Preschool, England, Follow-Up Studies, Humans, Immunization Schedule, Immunization, Secondary, Infant, Meningococcal Infections, Vaccines, Conjugate, Meningococcal Vaccines, Immunity, Herd, Neisseria meningitidis, Serogroup C

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks